SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US OTC > Biotechs >

Galectin Therapeutics Inc. (GALT)

GALT RSS Feed
Add GALT Price Alert      Hide Sticky   Hide Intro
Moderator: Chess Master, GREGG THE GREEK
Search This Board: 
Last Post: 9/22/2017 11:42:12 PM - Followers: 73 - Board type: Free - Posts Today: 0

Galectin Therapeutics is a biotechnology company focused on discovery and development. We apply our leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on our unique carbohydrate technology target galectin proteins, which are key mediators of biologic and pathologic function.

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Our strategy is to establish clinical development approaches that add value to the Company in the shortest time possible, and to seek partners as the program advances and requires much greater resources.

Galectin Therapeutics leverages extensive scientific and development expertise as well as established relationships with outside sources to achieve cost effective and efficient development. We are pursuing a clear development pathway to clinical enhancement and commercialization for our lead compounds in liver fibrosis and cancer immunotherapy.
 

Galectin Therapeutics is pursuing therapies for indications in which galectins have a demonstrated role in the pathogenesis of a particular disease. We focus on diseases with serious, life-threatening consequences to patients, and those where current treatment options are limited. Though we do not have any current marketed products, our research and development programs, designed to ultimately help patients and their physicians, are focused on:

 

Fibrosis

 

Fibrosis is the development of excess fibrous connective tissue in an organ when exposed to a chronic disease. The longer the disease affects the organ, the more fibrous tissue is deposited and this ultimately results in the failure of the organ. Galectin Therapeutics’ drug candidates provide a promising and exciting new approach for the treatment of fibrotic diseases, including liver, lung and kidney fibrosis. Significant unmet need exists for treatment options in fibrosis. For example, there are currently no approved medical treatments available for the millions of patients in the U.S. who have non-alcoholic steatohepatitis with advanced fibrosis – commonly known as fatty liver disease. Learn about fibrosis and our research in this area including galectin effects on liver fibrosis, lung fibrosis and kidney fibrosis.

 

Cancer

 

Cancer harms the body when damaged cells divide uncontrollably to form lumps or masses of tissue called tumors. Research shows the potential for galectin inhibition to play an important role in cancer therapy, particularly tumor immunotherapy – an emerging treatment that enhances the activity of the immune system against cancer cells. There are more than 100 types of cancers, and for many of these cancers, few treatment options exist. Our drug candidates provide a new and complimentary approach to other drugs on the market for the treatment of cancer. Learn more about cancer and immunotherapy.

 

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
GALT
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
GALT News: Current Report Filing (8-k) 09/22/2017 05:02:43 PM
GALT News: Galectin Therapeutics Receives Notice of Chinese Allowance to Grant a Key Patent for Composition of Matter for GR-MD-02 09/12/2017 08:30:00 AM
GALT News: Amended Statement of Beneficial Ownership (sc 13d/a) 09/08/2017 05:30:06 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 09/08/2017 04:49:39 PM
GALT News: Statement of Changes in Beneficial Ownership (4) 09/08/2017 04:47:47 PM
News News Alert: Current Report Filing (8-k) 09/22/2017 05:02:43 PM
PostSubject
#3200   That is an interesting 8-K... thefamilyman 09/22/17 11:42:12 PM
#3199   Did ChessMaster bail on it too, like gss2003 09/19/17 08:19:02 PM
#3198   Completely agree on downside and more possibility of Amatuer17 09/19/17 07:21:57 PM
#3197   I had sold my last shares in May biotech2010 09/19/17 11:15:18 AM
#3196   The upside is worth the risk on this one! BIGT80 09/15/17 10:04:12 PM
#3195   GALT financials O/s shares - 34 million Warrants/stock options - Amatuer17 09/14/17 10:04:28 PM
#3194   Actually I went with Jan 2018 options based Amatuer17 09/14/17 03:20:05 PM
#3193   Stock is $1.67 gss2003 09/14/17 12:47:23 PM
#3192   Company is maintaining the Dec 2017 deadline as Amatuer17 09/14/17 11:23:03 AM
#3191   Is it December yet? Noticed the short jmh0602 09/13/17 12:39:55 PM
#3190   "Pfizer has started testing an experimental medicine for Amatuer17 08/29/17 11:33:33 PM
#3189   we don't have a partner for psoriasis so jmh0602 08/21/17 06:09:15 PM
#3188   Was the reference to the 3 AD patients gss2003 08/18/17 10:12:06 AM
#3187   It really depends on how well it works. gss2003 08/17/17 08:15:34 PM
#3186   Realistically probably 10 billion. Share price well biotechexpert 08/16/17 07:26:09 PM
#3185   Early 2018 for combo therapy next readout, after gss2003 08/16/17 03:30:13 PM
#3184   How much is the company worth if the jmh0602 08/16/17 01:52:31 PM
#3183   Thera are also melanoma results coming. I think Coolec78 08/15/17 07:11:42 PM
#3182   Doesn't seem very encouraging given the longs are gss2003 08/15/17 10:40:40 AM
#3181   This is now a binary event stock - Amatuer17 08/15/17 05:59:20 AM
#3180   I am not normally one that I would RyGuy 08/11/17 12:15:17 PM
#3179   Yes, why no partnerships to explore other Gal-3 gss2003 08/11/17 11:21:26 AM
#3178   We will not hear anything till Dec from Amatuer17 08/10/17 07:01:14 PM
#3177   Not hearing much on the drug.... GALT has RyGuy 08/10/17 12:42:26 PM
#3176   The extension study is open label and everyone swing4fence 08/05/17 06:42:55 PM
#3175   The next 4 1/2 months will be just Amatuer17 08/04/17 07:41:00 AM
#3174   Pretty big price drop over the past week BIGT80 08/03/17 07:47:33 PM
#3173   interesting last hour. looks to me like jmh0602 08/03/17 05:23:44 PM
#3172   What happened today? Why spiked? Coolec78 08/03/17 04:56:22 PM
#3171   No I suck at that too. IRAHopeful 08/02/17 03:52:14 PM
#3169   I read the transcript of the slingshot interview. IRAHopeful 07/31/17 03:30:23 PM
#3168   Did anyone listen to conf? Stock is taking a beating Amatuer17 07/27/17 03:53:04 PM
#3167   NASH Conf Call Tomorrow 11AM Only serious Chess Master 07/26/17 06:53:43 PM
#3166   GRMD02 will work on Immunotherapy yes but what Chess Master 07/26/17 06:47:17 PM
#3165   immuno news . question Is Galectin protein stalker rickyricks 07/25/17 10:06:57 AM
#3164   The July 13 presentation is now in the jmh0602 07/24/17 12:14:32 PM
#3163   In the PR they said recording will be Amatuer17 07/18/17 02:57:30 PM
#3162   No, not sure there is one. I thought gss2003 07/18/17 12:53:05 PM
#3161   Has anyone found the recorded webcast for the conf? Amatuer17 07/17/17 08:45:43 PM
#3160   Thanks for the article Interesting to see mention of Amatuer17 07/10/17 09:08:30 PM
#3159   article on NASH - Jim is part of jmh0602 07/10/17 02:12:46 PM
#3158   Yes they are very different trials but the Amatuer17 06/25/17 10:29:21 AM
#3157   FX and CX two very different trials. biotechexpert 06/24/17 02:26:21 AM
#3156   The failed FX trial is creating doubt in Amatuer17 06/23/17 06:14:56 AM
#3155   "This trial was designed and is being conducted jmh0602 06/22/17 08:38:16 PM
#3154   Agreed 100% no side effects and low drop Chess Master 06/19/17 08:55:30 PM
#3153   I checked the clinical study site. IRAHopeful 06/19/17 01:37:13 PM
#3152   I don't know what the symptoms are for IRAHopeful 06/19/17 12:07:58 PM
#3151   Extremely low drop out rate. Patients must biotechexpert 06/14/17 09:22:07 PM
#3150   Not a bad strategy. How much are $5 gss2003 06/14/17 12:36:44 PM
PostSubject